Hartmut Bertz

Featured in: Favicon

Articles

Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) | Bone Marrow Transplantation

Mar 15, 2024 | nature.com | Jürgen Finke |Francis Ayuk |Hartmut Bertz |Eva-Maria Wagner

AbstractATOS is a prospective observational study evaluating the outcome of patients receiving anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation. Primary endpoint was severe GvHD and relapse-free survival (SGRFS). GvHD prophylaxis consisted of ATLG and CSA/ MTX or MMF. Outcome was compared to the ATLG arm of our prospective randomized phase III multicenter trial trial (RCT) [1, 2].

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.